Nextbiomedical Co. Ltd. engages in the development of therapeutics based on polymer and drug delivery system technologies. Its products include Nexpowder: Hemostatic Systems for Endoscopy, Nexsphere: Resorbable Gelatin Microspheres for Tailored Embolization, Nexsphere-F: Fast-Resorbable Gelatin Microspheres for Musculoskeletal Embolization and NexGel: Resorbable Gelatin Microparticle for Embolization. The company was founded on August 1, 2014 and is headquartered in Incheon, South Korea.